Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TETHER

Financiado

Cerrado

Targeting the essentialome of radiotherapy resistant cancer

"More than 50% of the cancer patients undergo irradiation as part of their cancer treatment. Although radiotherapy (RT) significantly contributes to cancer cure, local therapy resistance and the subsequent emergence of distant met... ver más

30/09/2026

UNIVERSITAET BERN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-28

ERC-2019-ADG: ERC Advanced Grant

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITAET BERN

2.50M€ | Lider

UNOPAN TABLEROS DE FIBRAS S....

1.42M€ | Participante

Proyectos interesantes

RhabdoEvo

Medical Technol...

Data Science

2M€ Cerrado

BRCAstem

Medical Technol...

Data Science

225K€ Cerrado

CanSel

Medical Technol...

Data Science

166K€ Cerrado

TargetBRCA

Medical Technol...

Data Science

150K€ Cerrado

3DBREASTCANCER

Medical Technol...

Data Science

100K€ Cerrado

PARPinhibit

Medical Technol...

Data Science

251K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 76 meses Fecha Inicio: 2020-05-28
Fecha Fin: 2026-09-30

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "More than 50% of the cancer patients undergo irradiation as part of their cancer treatment. Although radiotherapy (RT) significantly contributes to cancer cure, local therapy resistance and the subsequent emergence of distant metastasis remain major obstacles for its success. The molecular mechanisms underlying tumor cell-intrinsic RT resistance are ill-defined. It is therefore crucial to better define these mechanisms and identify new vulnerabilities of RT-resistant tumors in order to decrease the current annual cancer mortality of >1.3 million persons in EU member states alone. In the TETHER project, I will address the problem of RT resistance by synergizing the power of genetic essentiality analyses with unique mouse models and organoids that we have established. We recently found that members of the shieldin and CST complexes are essential for tumor cells to survive irradiation, while causing PARP inhibitor resistance when lost in BRCA1-deficient tumors. Based on this unexpected finding, I have started a new line of research to dissect the RT ""essentialome"". As I show with the discovery and functional characterization of ERCC6l2 as a novel DNA repair factor in this network, the technology we have in place is perfectly suited to tackle this question. In addition, we will apply distinct CRISPR/Cas9-based tests to map the functional interactome of genes that are essential for RT resistance. To follow the plasticity and RT escape of tumor cells in vivo, we have also developed innovative model systems. Similar to the situation in cancer patients, we observe that residual cancer cells in our mouse models escape the deadly effects of RT by local resistance or metastasis formation. Thus, these models provide a unique opportunity to explore and target RT escape mechanisms. I am convinced that the combination of these state-of-the-art approaches will yield highly useful information for designing individualized approaches to improve RT response in cancer patients. "

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores